634 • CID 2005:41 (1 September) • Roden et al.
M A J O R A R T I C L E
Epidemiology and Outcome of Zygomycosis:
A Review of 929 Reported Cases
Maureen M. Roden,1Theoklis E. Zaoutis,2,3,4Wendy L. Buchanan,1Tena A. Knudsen,1Tatyana A. Sarkisova,1
Robert L. Schaufele,1Michael Sein,1Tin Sein,1Christine C. Chiou,6Jaclyn H. Chu,2Dimitrios P. Kontoyiannis,5
and Thomas J. Walsh1
1Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland;
of Philadelphia, and
of Medicine, Philadelphia, Pennsylvania;
2Division of Infectious Diseases, The Children’s Hospital
4Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School
5M. D. Anderson Cancer Center, University of Texas, Houston; and
3Department of Pediatrics and
6National Yang Ming University,
hensive literature review that describes the epidemiology and outcome of this disease.
We reviewed reports of zygomycosis in the English-language literature since 1885 and analyzed 929
eligible cases. We included in the database only those cases for which the underlying condition, the pattern of
infection, the surgical and antifungal treatments, and survival were described.
The mean age of patients was 38.8 years; 65% were male. The prevalence and overall mortality were
36% and 44%, respectively, for diabetes; 19% and 35%, respectively, for no underlying condition; and 17% and
66%, respectively, for malignancy. The most common types of infection were sinus (39%), pulmonary (24%), and
cutaneous (19%). Dissemination developed in 23% of cases. Mortality varied with the site of infection: 96% of
patients with disseminated disease died, 85% with gastrointestinalinfectiondied,and76%withpulmonaryinfection
died. The majority of patients with malignancy (92 [60%] of 154) had pulmonary disease, whereas the majority
of patients with diabetes (222 [66%] of 337) had sinus disease. Rhinocerebral disease was seen more frequently
in patients with diabetes (145 [33%] of 337), compared with patients with malignancy (6 [4%] of 154). Hema-
togenous dissemination to skin was rare; however, 78 (44%) of 176 cutaneous infections were complicated by
deep extension or dissemination. Survival was 3% (8 of 241 patients) for cases that were not treated, 61% (324
of 532) for cases treated with amphotericin B deoxycholate, 57% (51 of 90) for cases treated with surgery alone,
and 70% (328 of 470) for cases treated with antifungal therapy and surgery. By multivariate analysis, infection
due to Cunninghamella species and disseminated disease were independently associated with increased rates of
death (odds ratios, 2.78 and 11.2, respectively).
Outcome from zygomycosis varies as a function of the underlying condition, site of infection,
and use of antifungal therapy.
Zygomycosis is an increasingly emerging life-threatening infection. There is no single compre-
Zygomycosis has emerged as an increasingly important
pathogen during the past decade [1–5]. This increase
has been particularly evident in hematopoieticstemcell
transplant recipients and patients with hematological
malignancies [6–12]. Unlike other filamentous fungi
that are largely opportunistic in patients with cancer,
transplant recipients, and patients with inherited im-
munodeficiencies, zygomycosis also can be a frequently
Received 27 January 2005; accepted 18 April 2005; electronically published 29
Reprints or correspondence: Dr. Thomas J. Walsh, Pediatric Oncology Branch,
National Cancer Institute, CRC, 1W, 1-5740, 10 Center Dr., Bethesda, MD 20892
Clinical Infectious Diseases 2005;41:634–53
? 2005 by the Infectious Diseases Society of America. All rights reserved.
lethal infection in hosts with greater immunocompe-
tency, such as those with diabetes mellitus [13–23],
drug users (IDUs) [33–39], and those with no apparent
immune impairment [40–46].
To date, there has been no definitive, comprehensive
review of the literature on zygomycosis to guide our
understanding of the epidemiology and outcome of
zygomycosis in the general population. We therefore
reviewed the English-language literature for all cases of
zygomycosis, from the original case report in 1885 to
the present. In this review, we sought to understand
the distribution of infection within the general popu-
lation and to ascertain whether the patternsofinfection
are associated with specific host factors and outcomes.
Epidemiology of Zygomycosis • CID 2005:41 (1 September) • 635
zygomycosis, 504 of whom died.
Demographic and clinical characteristics of 929 patients with
Characteristic All patients
No underlying condition at time of in-
fection, cause of infection
Underlying condition at time of infection
Solid organ transplantation
Injection drug use
Bone marrow transplantation
Low birth weight infant
Diarrhea and malnutrition
Systemic lupus erythematosus
aData are no. of patients with the characteristic who died/total no. with the charac-
bIncludes hepatic disease, hematologic disorders,metabolicacidosis,tuberculosis,and
Data are proportion (%) of patients, unless otherwise specified.
We initiated our search by reviewing all references from the
chapters of major books written on the subject of zygomycosis.
We then carefully scrutinized the references for single case re-
ports or case series. We then expanded this initial review by a
MEDLINE search using the following key words: zygomycosis,
mucormycosis, phycomycosis, Rhizopus, Mucor, Rhizomucor,
Cunninghamella, Absidia, Apophysomyces, Syncephalastrum,
idiobolus. After this initial series of reports was reviewed, the
individual references listed in each publication were again re-
viewed for ascertainment of additional case reports.
Criteria for inclusion of zygomycosis case reports
Only those case reports that included data on the following 6
variables were included in our review.
to be confirmed either histologically or by culture.Information
about whether the infection was documented premortem or
postmortem also was required.
Anatomical location of infection.
primary site of infection at the time of diagnosis and whether
the infection remained localized or disseminated was required.
Disseminated infection was defined as infection at ?2 non-
contiguous sites. Patients with disseminated infection at the
time of diagnosis for which the primary site of infection was
impossible to identify were classified as having generalized dis-
seminated infection. Patients with cutaneous infection were
subcategorized into 3 groups. Patients in whom the infection
was confined to the cutaneous or subcutaneous tissue were
defined as having localized disease. Patients with invasion into
muscle, tendon, or bone were classified as having deep exten-
sion of infection. Patients with cutaneous disease involving
Documentation of the
636 • CID 2005:41 (1 September) • Roden et al.
Incidences of zygomycosis over 6 decades (1940–1999), by host population
another noncontiguous site were defined as having dissemi-
nated infection. Patients with pulmonary infection were sub-
categorized in a similar manner, as follows: those with disease
confined to the lungs were classified as having localized infec-
tion; those with disease that extended to the chest wall, pul-
monary artery, aorta, or heart were defined as having deep
extension of infection; and those with demonstrated involve-
ment of a noncontiguous site were defined as having dissem-
We were especially careful to subcategorize patients with si-
nus involvement, because we found “rhinocerebral” to be an
overused term for this infection. Consequently, we distin-
guished patients withtruecerebralinvolvementfromthosewith
localized sinus disease. We also separately categorized patients
on the basis of sino-orbital involvement and sinopulmonary
disease. Patients with disease confined to the paranasal sinuses
were defined as having sinusitis; those with disease in the par-
anasal sinuses and infiltrating the orbit were defined as having
sino-orbital infection; those with disease in the paranasal si-
nuses and the brain were categorized as having rhinocerebral
infection, with cerebral involvement defined as tissue invasion
demonstrated histologically or by culture during life or at au-
topsy, radiological evidence of disease by either CT or MRI, or
severe neurological impairment; and those with disease in the
paranasal sinuses and lungs were defined as having sinopul-
Documentation of the primary un-
derlying condition or of immunosuppression was required for
each reported case, unless the patient was described as having
no underlying condition.
the presence or absence of both surgery and antifungal therapy
Documentation of antifungal therapy.
with a documented absence or specific presence of antifungal
therapy were included in the review. When not specified, we
estimated the approximate duration of amphotericin B therapy
for adult patients by dividing the total dose by 70 kg and
assuming a dosage of 1 mg/kg per day.
Mortality was assessed as all-cause mortality
during the course of zygomycosis.
Only those cases that specified
Only those patients
Filemaker Pro software, version 5.5 (Filemaker), was used to
develop a database of categorical and continuous variables.The
categorical variables included sex, underlying diagnosis, dia-
betes (type and presence of ketoacidosis), neutropenic status,
infecting organism, diagnostic method used for recovery of
infecting organism, premortem or postmortem diagnosis, in-
fection site (focal or disseminated disease), surgery, hyperbaric
oxygen therapy, immunomodulation, and outcome. The con-
tinuous variables included year of diagnosis, year of case pub-
lication, age of patient, and dose and/or duration of antifungal
Patterns of zygomycosis, by host population
638 • CID 2005:41 (1 September) • Roden et al.
cosis, 504 of whom died.
Infection patterns among 929 patients with zygomy-
Type of infection, by site
of all patients
No. of patients
with the infection
who died/total no.
with the infection (%)
Other solid organ
because patients with infection at 11 site are counted more than once. Thus,
988 sites are reported for all patients, and 561 sites are reported for patients
aPatients with rhinocerebral infection and those with localized cerebral in-
fection together constituted 283 patients (30%).
bIncludes peritoneum, mastoid, oral mucosa, bone, and bladder.
Patient counts in each column total to more than the n values
therapy. When available, additional information regarding se-
rum ferritin, transferrin, and transferrin saturation levels, as
well as glucose and bicarbonate levels, were recorded.
Univariate analyses were conducted to determine the associa-
tion between potential risk factors and death. Categorical var-
iables were compared by x2analysis or Fisher’s exact test,
whereas continuous variables were compared by the Wilcoxon
rank-sum test. All variables with a P value of !.20 on univariate
analysis were considered for inclusion in a multivariate model,
as were those variables noted to be confounders on stratified
analysis. Multivariate analysis was performed using logistic re-
gression methods. Survey estimation was applied to the logistic
regression models, to adjust for the modest degree of case clus-
tering among the reporting sites. Clustering was evident from
estimates of statistically significant but modest interclass cor-
relation (by site). The analyses used standard algorithms as
described by Korn and Graubard  to determine variance
estimates for this correlation. Construction of the multivariate
model began with inclusion of certain variables (i.e., dissemi-
nated disease and therapy) considered to be important on the
basis of a priori hypotheses. Reported CIs are therefore some-
what more conservative (wider) and P values are somewhat
larger than would be estimated by conventional logistic re-
gression methods. A 2-tailed P value of !.05 was considered
to be statistically significant. All statistical calculations were
performed using standard programs in Stata, version 7.0
The first case of zygomycosis reported in the literature was by
Paultauf in 1885 . This case, however, did not meet the
predefined eligibility criteria and, consequently, was not in-
cluded in our database. The first case to be included was re-
ported in 1940. A total of 1049 individual cases of zygomycosis
from 1940 through 2003 were identified. Of these, 120 cases
were excluded from the database because they did not meet
the stringent predefined inclusion criteria. The total database
thus consisted of 929 cases (in 1 patient each) reported in 459
published reports [14–476].
and their associated all cause mortality are summarized intable
1. The mean age was 38.8 years, and the median age was 40.0
years (range, 0.005–80 years). A total of 65% of allZygomycetes
infections occurred in males. The overall mortality in the total
population was 54% (504 of 929 patients).
Diabetes was the most common underlying condition. Only
68 patients (20%) with diabetes had type I diabetes, and of
these, 33 (48%) had documented ketoacidosis. Conversely,
most patients with diabetes in this review had type II diabetes
(), with 64 (34%) having documented ketoacidosis. In
n p 187
54 (16%) of 337 patients with diabetes, zygomycosis presented
as the diabetes-defining illness. The second largest patientpop-
ulation consisted of persons who had no primary underlying
disease at the time of infection. Among 154 patients with ma-
lignancy, 147 (95%) had a hematological malignancy. There
were only 7 cases of zygomycosis reported in patients with a
Secular trends in reported hosts.
the reporting of zygomycosis in all underlying host populations
during the study period (figure 1). Diabetes was the most com-
monly reported underlying condition in each decade.However,
an increasing proportion of other host populations, including
those with malignancy, recipients of bone marrow transplants,
The underlying conditions
There was an increase in
Epidemiology of Zygomycosis • CID 2005:41 (1 September) • 639
Percentages of zygomycosis cases documented by culture since the 1940s, by decade
recipients of deferoxamine, IDUs, and patients with no un-
derlying condition becomes apparent in the 1980s and 1990s.
Sites and patterns of infection.
tion at the time of initial diagnosis varied as a function of the
host population (figure 2). Sinus involvement consisting of
rhinocerebral, sinus, and sino-orbital infections constitutedthe
majority of infections (222 [66%] of 337) in patients with
diabetes. This differs from the pattern of infection in persons
with no underlying condition, in which cutaneouszygomycosis
constituted one-half of all cases. By further comparison, pul-
monary zygomycosis constituted more than one-half of all sites
of infection in patients with malignancy and recipients of bone
marrow transplants. Sinus involvement was the second most
common pattern of infection in this patient population. Pa-
tients undergoing solid organ transplantation had another dis-
tinctive pattern, with relatively similar frequencies of pulmo-
nary and sinus infections. On the other hand, patientsreceiving
deferoxamine therapy presented more frequently with gener-
alized disseminated zygomycosis, compared with other host
categories. Finally, cerebral zygomycosis was the most common
presenting pattern of infection in IDUs. The pattern of cerebral
zygomycosis in IDUs was hematogenous and was seldom as-
sociated with rhinocerebral infection.
The patterns of infection and their associated all-cause mor-
tality are detailed in table 2. The paranasal sinuses were the
most common site of infection, presenting in 39% of cases.
Rhinocerebral infection was the most commonly reported pat-
tern of sinus zygomycosis. Independent predictors for sinus
zygomycosis were diabetes type 1 (OR, 4.04; 95% CI, 2.36–
6.90), diabetes type 2 (OR, 6.35; 95% CI, 3.89–10.36), and
injection drug use (OR, 0.15; 95% CI, 0.04–0.51). Pulmonary
The primary site of infec-
disease was the second most common presenting pattern. Ap-
proximately one-half of all cases were restricted to the lung,
whereas the remaining cases were either disseminated or com-
plicated by deep extension into the chest wall, pulmonary ar-
tery, or heart. Independent risk factors for pulmonary zygo-
mycosis were infection with Cunninghamellaspecies(compared
with infection with Rhizopus species) (OR, 7.75; 95% CI, 2.44–
24.58), neutropenia (OR, 2.28; 95% CI, 1.26–4.11), and receipt
of a solid organ transplant (OR, 3.41; 95% CI, 1.41–8.20).
Cutaneous involvement was the presenting pattern in 176
(19%) of 929 patients. Penetrating trauma was reported for 60
(34%) of these patients, dressings were reported for 26 (15%),
surgery was reported for 26 (15%), burns were reported for
11 (6%), motor vehicle accident was reported for 5 (3%), and
falls were reported for 5 (3%). The histories for the remaining
42 patients (24%) were not well described. Most cases were
localized to the integument. However, deep extension to bone,
tendon, or muscle occurred in 42 (24%) of 176 cases, and
organs occurred in 35 (20%). Hematogenous dissemination
from other organs to skin occurred rarely, in only 6 cases (3%).
The majority of patients with cutaneous infection were either
nonneutropenic or had no underlying condition. Independent
risk factors for localized cutaneous infection were female sex
(OR, 2.27; 95% CI, 1.46–3.55), no underlying condition (OR,
2.60; 95% CI, 1.32–5.14), prior surgery (OR, 5.40; 95% CI,
1.84–15.86), and HIV infection (OR, 2.62; 95% CI, 1.01–6.79).
There were 283 patients with CNS infection, of which 69%
had rhinocerebral infection, 16% had localized cerebral infec-
tion, and 15% had hematogenous dissemination of infection
from other organs to the brain. Both rhinocerebral infection
640 • CID 2005:41 (1 September) • Roden et al.
mycosis, 219 of whom died.
Microbiological findings for 465 patients with zygo-
of all patients
No. of patients
who died/total no.
with the organism (%)
pendent variables, including species-related host factors and patterns of
Interspecies differences in mortality may be due to other code-
sex in 465 cases of culture-confirmed zygomycosis.
Relationship between microbiologic findings and male
No. of cases
of cases (%)
and localized cerebral infection were associated withamortality
of 62%. Of patients with localized cerebral infection, mostwere
IDUs who were independently associated withthedevelopment
of primary CNS disease (OR, 80.25; 95% CI, 26.69–241.28).
There were no patients with diabetes who had hematogenous
dissemination to the brain. Instead, all CNS infections in pa-
tients with diabetes occurred in those with rhinocerebral
Gastrointestinal infection occurred in 65 patients (7%). The
rate of dissemination to other noncontiguous organs was 38%
(25 of 65 patients). Mortality was high, primarily because of
bowel perforation. The infection occurred predominantly in
low birth weight infants, patients with diarrhea and malnutri-
tion, and patients receiving peritoneal dialysis.
The risk for development of disseminated zygomycosis from
any site varied as a function of host characteristics.Independent
risk predictors were burns (OR, 6.26; 95% CI, 1.16–33.81),
prematurity (OR, 2.85; 95% CI, 1.26–6.43), deferoxamine use
(OR, 2.76; 95% CI, 1.66–4.59), diabetes (OR, 0.29; 95% CI,
0.17–0.50), no underlying condition (OR, 0.47; 95% CI, 0.25–
0.91), and HIV infection (OR, 0.15; 95% CI, 0.03–0.63).
Microbiologic and histopathologic findings.
had infection documented either histologically or by culture.
A positive culture result was obtained in 50% of cases (table
3). There was a clear increase in culture positivity over time,
with 71% of all cases since 2000 diagnosed on the basis of
culture results (figure 3). Among the 465 cases with a culture
positive for a Zygomycetes organism, Rhizopus species were the
most commonly recovered organisms, with Rhizopus oryzaethe
most frequently recovered species.
Sex and zygomycosis.
Zygomycosis occurred primarily in
males (605 [65%] of 929 cases). The following genera were
clearly associated with infection in males, constituting 178%
of infections in this group: Basidiobolus, Cunninghamella, Ab-
sidia, and Apophysomyces (table 4).
Entomophthorales organisms caused 7.2% of all zygomy-
coses in this review. The order Entomophthorales differedfrom
the order Mucorales in overall survival (69% vs. 52%) and in
the frequency of persons with no underlying condition (69%
vs. 50%). Of infections due to Conidiobolus species, 5 (50%)
of 10 were cutaneous. Of infections due to Basidiobolusspecies,
7 (78%) of 9 were gastrointestinal.
Of the 929 cases reviewed, 596 (64%) were
treated with some form of antifungal chemotherapy (table 5).
Survival in this group was 62% (369 of 596 patients). Of these
596 patients, 532 (89%) received amphotericin B deoxycholate,
with an overall survival of 61%. Survival was 57% (51 of 90
patients) for those treated with surgeryalone;survivalincreased
to 70% (328 of 470 patients) for those treated with a combi-
nation of surgery and antifungal chemotherapy. A total of 241
patients (26%) received no treatmentfortheirinfection.Within
this subgroup, the survival rate was 3% (8 of 241 patients).
Analysis of survival by decaderevealedthatover-
all mortality improved from 84% in the 1950s to 47% in the
1990s (figure 4). However, mortality due to zygomycosis has
remained essentially unchanged since the 1960s, when ampho-
tericin B deoxycholate was widely introduced (figure 5).
Table 6 summarizes results of the multivariate regression
analysis of risk factors for mortality among all patients. Sig-
nificant risk factors for mortalityincludeddisseminateddisease,
Epidemiology of Zygomycosis • CID 2005:41 (1 September) • 641
Treatment administered to 929 patients with zygomycosis, 425 of whom
of all patients
No. of patients
who survived/total no.
the treatment (%)
Amphotericin B formulation
Itraconazole, ketoconazole, or posaconazole
No antifungal therapy
Surgery and antifungal chemotherapy
Granulocyte colony-stimulating factor
Mortality due to zygomycosis since the 1940s, by decade
renal failure, and infection with Cunninghamella species. Con-
versely, type I diabetes and no underlying condition were in-
dependently associated with a reduced risk of death. Compared
with no receipt of antifungal therapy, all forms of antifungal
therapy were also significantly associated with a reduced risk
of mortality. Patients who underwent surgery as primary ther-
apy were also significantly more likely to survive. Pulmonary,
rhinocerebral, kidney, and gastrointestinal infection were as-
sociated with the highest risks of mortality.
Zygomycosis was first reported as a cause of human disease in
1885 . Unlike other filamentous fungal pathogens that tar-
get immunocompromised hosts, Zygomycetes organismsinfect
a broader and more heterogeneous population. In this review,
persons with no underlying condition and patients with dia-
betes represented 150% of all infected patients. In the past 20
years, there also has been an emergence of this infection in the
more classically defined immunocompromised risk groups,
such as patients with hematological malignancy, recipients of
a bone marrow transplant, and recipients of a solidorgantrans-
Zygomycetes organisms are unique among filamentous fun-
gi because of their disproportionately high capacity to cause
devastating disease in persons with no underlying condition.
Among persons with no underlying condition who had a his-
642 • CID 2005:41 (1 September) • Roden et al.
Median duration of polyene therapy for patients with zygomycosis who survived or who died, by host population
patients with zygomycosis.
Multivariate model of risk factors for mortality among
VariableOR (95% CI)P
Extent of infection
No underlying condition
Amphotericin B deoxycholate only
Lipid amphotericin only
Amphotericin formulation and azole
Surgery as primary therapy
of site-specific infections are (with cutaneous infections as the reference):
pulmonary infection (OR, 7.50; 95% CI, 2.84–19.80;
infection (OR, 6.39; 95% CI, 2.64–15.48;
8.30; 95% CI, 2.54–27.16; ), and gastrointestinal infection (OR,22.51;Pp .001
95% CI, 5.50–92.14; ).Pp!.001
Additional risk factors included within a similar model for analysis
), kidney infection (OR,Pp!.001
tory of burns, surgery, or trauma, the majority (63 [73%] of
87) presented with cutaneous disease. In the subgroup of per-
sons with no underlying condition, only 25 (28%) of 89 pre-
presented with deeply invasive infection.
Cutaneous inoculation from a Zygomycetes organism may
have underestimated consequences. Of all cutaneous infections
in this review, 43 (24%) of 176 deeply extended to tendon,
muscle, or bone. Moreover, an additional 35 (20%) of 176
patients with cutaneous disease developed hematogenous dis-
semination from the original cutaneous site to another organ,
resulting in an overall mortality of 94% (33 of 35 patients) in
this subgroup. Unlike other filamentous fungi that will he-
matogenously disseminate from another organ to skin, we
found converse behavior in this review. There were 220 cases
of hematogenously disseminated infection, yet only 6 had doc-
umented cutaneous involvement. Of the 4 cases in which cul-
ture was performed, 3 were due to Rhizomucor pusillus, which,
overall, is a relatively uncommon pathogen [49–51].
Cerebral infection was the most common presentation of
zygomycosis in IDUs. This pattern occurred in the absence of
sinusitis or rhinocerebral disease and appears tohavedeveloped
hematogenously. Because Zygomycetes organisms are ubiqui-
tous, contamination of injected illicit drugs seems to be likely.
If some of the injected sporangiospores are not adequately fil-
tered by the pulmonary capillary bed, they will enter the sys-
temic arterial circulation, where ∼25% of the cardiac output is
distributed to the brain. Particulate material the size of spor-
angiospores tend to distribute either to the gray-white junction
of the brain or to the basal ganglia via the striatal arteries. The
vast majority of the infections we reviewed presented in the
We found that patterns of infection differ as a function of
host characteristics. The relationships between persons with no
underlying condition and cutaneous involvement and between
IDUs and cerebral involvement seems to be logical. However,
the strong association between both malignancy and bonemar-
Epidemiology of Zygomycosis • CID 2005:41 (1 September) • 643
between diabetes and sinus involvement is more complicated.
Perhaps one sees a preponderance of pulmonary disease in the
population with malignancies as the result of chemotherapy-
related defects in innate pulmonary host defenses that are as-
sociated with neutropenia and with chemotherapy-induced
mucociliary dysfunction. The factors contributing to sinus in-
volvement in patients with diabetes maybemoremultifactorial.
Patients with diabetes have more microvascular disease, and
perhaps this, in concert with the delicate architecture of the
sinuses, may result in more tissue destruction and local
The patterns of infection due to deferoxamine demonstrated
the highest level of generalized disseminated infection (23%),
compared with any other pattern. This finding underscores the
importance of iron in the virulence of Zygomycetes organisms.
When circulating deferoxamine molecules bind to host iron,
the deferoxamine serves as a sideophore to the Zygomycetes
organism. This iron-enriched systemic milieu tips the host-
parasite balance in favor of the pathogen.
This study documents that the capacity to recover these or-
ganisms by culture has significantly improved over time. This
improvement may be due to better training among mycology
technologists, a greater understanding of specimen processing
in the laboratory, improved culture techniques, and increased
access to sophisticated reference laboratories.
The reason for a higher prevalence of Zygomycetesinfections
among males is unclear. There is mycologic precedent for this
predisposition, as observed in the protective role of estrogen
in paracoccidioidomycosis . The potential role of estrogen
in Zygomycetes infection has not yet been explored.
There were 157 pediatric cases in this review. Underlying
host factors differed between adults and children: 17% of pe-
diatric infections occurred in low birth weight infants,and26%
were associated with diarrhea and malnutrition.
Most patients in this review who were treated withantifungal
chemotherapy received amphotericin B or one of its lipid for-
mulations. This is not surprising, because amphotericin B has
been essentially the only agent active against most Zygomycetes
species. There did appear to be some added benefit to receiving
surgery for the management of these infections. However, one
must exercise caution in extrapolating treatment choices on the
basis of these data, because all of the data are retrospective and
may be subject to a period effect (i.e., a change in the rate of
a condition irrespective of age and birth date) and publication
bias. Nevertheless, multivariate analysis clearly demonstrates
that antifungal therapy and surgery are independently associ-
ated with a decreased risk of mortality, with ORs of 0.9–0.24.
There has been little change in the overall mortality during the
past 40 years, since the introduction of amphotericin B. As
recognition of host groups and their risk factors for zygomy-
cosis increases, earlier intervention with antifungaltherapymay
improve the outcome of this devastating infection.
and Enzon Pharmaceuticals (to M.M.R.).
Potential conflicts of interest.
Schering Plough Research Institute (to M.M.R.)
All authors: no conflicts.
1. Gonzalez CE, Rinaldi MG, Sugar AM. Zygomycosis. Infect Dis Clin
North Am 2002;16:895–914.
2. Greenberg RN, Scott LJ, Vaughn HH, Ribes JA. Zygomycosis (mu-
cormycosis): emerging clinical importance and new treatments. Curr
Opin Infect Dis 2004;17:517–25.
3. Kauffman CA. Zygomycosis: reemergence of an old pathogen. Clin
Infect Dis 2004;39:588–90.
4. Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: a
review of the clinical manifestations, diagnosis and treatment. Clin
Microbiol Infect 2004;10 (Suppl 1):31–47.
5. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetesinhumandisease.
Clin Microbiol Rev 2000;13:236–301.
6. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in
the 1990s in a tertiary-care cancer center. Clin Infect Dis 2000;30:
7. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and
outcome of mould infections in hematopoietic stem cell transplant
recipients. Clin Infect Dis 2002;34:909–17.
8. Pagano L, Ricci P, Tonso A, et al. Mucormycosis in patients with
haematological malignancies: a retrospective clinical study of 37cases.
GIMEMA Infection Program (Gruppo ItalianoMalattieEmatologiche
Maligne dell’Adulto). Br J Haematol 1997;99:331–6.
9. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a
tertiary-care cancer center in the era of Aspergillus-active antifungal
therapy: a case-control observational study of 27 recent cases. J Infect
10. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after
voriconazole treatment in recipients of hematopoietic stem-celltrans-
plants. N Engl J Med 2004;350:950–2.
11. Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, et al. Invasive
zygomycosis in hematopoietic stem cell transplantrecipientsreceiving
voriconazole prophylaxis. Clin Infect Dis 2004;39:584–7.
12. Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Break-
through fungal infections in stem cell transplant recipients receiving
voriconazole. Clin Infect Dis 2004;39:743–6.
13. Vazquez JA, Sobel JD. Fungal infections in diabetes. Infect Dis Clin
North Am 1995;9:97–116.
14. Adam RD, Hunter G, DiTomasso J, Comerci G Jr. Mucormycosis:
emerging prominence of cutaneous infections. Clin Infect Dis
15. Battock DJ, Grausz H, Bobrowsky M, Littman ML. Alternate-day
amphotericin B therapy in the treatment of rhinocerebral phyco-
mycosis (mucormycosis). Ann Intern Med 1968;68:122–37.
16. Ferguson BJ. Mucormycosis of the nose and paranasal sinuses. Oto-
laryngol Clin North Am 2000;33:349–65.
17. Gregory J, Golden A, Haymaker W. Mucormycosis of the central
nervous system: a report of three cases. Bull Johns Hopkins Hosp
18. Limongelli WA, Clark MS, Saglimbene R, Baden E, Washington JA,
Williams AC. Successful treatment of mucocutaneous mucormycosis
after dental extractions in a patient with uncontrolled diabetes. J Oral
19. Lowe JT Jr, Hudson WR. Rhincerebral phycomycosis and internal
carotid artery thrombosis. Arch Otolaryngol 1975;101:100–3.
644 • CID 2005:41 (1 September) • Roden et al.
20. Meyer RD, Armstrong D. Mucormycosis—changing status. CRC Crit
Rev Clin Lab Sci 1973;4:421–51.
21. Pillsbury HC, Fischer ND. Rhinocerebral mucormycosis. Arch Oto-
22. Rangel-Guerra RA, Martinez HR, SaenzC, Bosques-PadillaF,Estrada-
Bellmann I. Rhinocerebral and systemic mucormycosis: clinical ex-
perience with 36 cases. J Neurol Sci 1996;143:19–30.
23. Wasserman AJ, Shiels WS, Sporn IN. Cerebral mucormycosis. South
Med J 1961;54:403–10.
24. Boelaert JR, Fenves AZ, Coburn JW. Deferoxamine therapy and mu-
cormycosis in dialysis patients: report of an international registry.Am
J Kidney Dis 1991;18:660–7.
25. Boelaert JR, van Roost GF, Vergauwe PL, Verbanck JJ, de Vroey C,
Segaert MF. The role of desferrioxamine in dialysis-associated mu-
cormycosis: report of three cases and review of the literature. Clin
26. Eiser AR, Slifkin RF, Neff MS. Intestinal mucormycosis in hemodi-
alysis patients following deferoxamine. Am J Kidney Dis 1987;10:
27. Hamdy NA, Andrew SM, Shortland JR, et al. Fatal cardiac zygo-
mycosis in a renal transplant patient treated with desferrioxamine.
Nephrol Dial Transplant 1989;4:911–3.
28. Kaneko T, Abe F, Ito M, Hotchi M, Yamada K, Okada Y. Intestinal
mucormycosis in a hemodialysis patient treatedwithdesferrioxamine.
Acta Pathol Jpn 1991;41:561–6.
29. Prokopowicz GP, Bradley SF, Kauffman CA. Indolent zygomycosis
associated with deferoxamine chelation therapy. Mycoses 1994;37:
30. Seeverens HJ, Tijhuis GJ, Ruijs GJ, Kazzaz BA, Kauffmann RH. Di-
alysis associated mucormycosis and desferrioxamine treatment: a case
report with review of the role of oxygen radicals. Neth J Med 1992;41:
31. Virmani R, Connor DH, McAllister HA. Cardiac mucormycosis: a
report of five patients and review of 14 previously reported cases. Am
J Clin Pathol 1982;78:42–7.
32. Windus DW, Stokes TJ, Julian BA, Fenves AZ. Fatal Rhizopus infec-
tions in hemodialysis patients receiving deferoxamine. Ann Intern
33. Hopkins RJ, Rothman M, Fiore A, Goldblum SE. Cerebral mucor-
mycosis associated with intravenous drug use: three case reports and
review. Clin Infect Dis 1994;19:1133–7.
34. Lussier N, Laverdiere M, Weiss K, Poirier L, Schick E. Primary renal
mucormycosis. Urology 1998;52:900–3.
35. Nagy-Agren SE, Chu P, Smith GJ, Waskin HA, Altice FL. Zygomycosis
(mucormycosis) and HIV infection: report of three cases and review.
J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:441–9.
36. Pierce PF Jr, Solomon SL, Kaufman L, Garagusi VF, Parker RH, Ajello
L. Zygomycetes brain abscesses in narcotic addicts with serological
diagnosis. JAMA 1982;248:2881–2.
37. Raif K, Kua A, Nunez M, Zaman A, Seijo L. Renal abscess secondary
to mucormycosis in an AIDS patient. AIDS Read 1995:209–12.
38. Van den Saffele JK, Boelaert JR. Zygomycosisin HIV-positivepatients:
a review of the literature. Mycoses 1996;39:77–84.
39. Wetli CV, Weiss SD, Cleary TJ, Gyori E. Fungal cerebritis from in-
travenous drug abuse. J Forensic Sci 1984;29:260–8.
40. Blair JE, Fredrikson LJ, Pockaj BA, Lucaire CS. Locally invasive cu-
taneous Apophysomyces elegans infection acquired from snapdragon
patch test. Mayo Clin Proc 2002;77:717–20.
41. Chakrabarti A, Kumar P, Padhye AA, et al. Primary cutaneous zyg-
omycosis due to Saksenaea vasiformis and Apophysomyces elegans.Clin
Infect Dis 1997;24:580–3.
42. Martinson FD, Clark BM. Rhinophycomycosis entomophthorae in
Nigeria. Am J Trop Med Hyg 1967;16:40–7.
43. Mooney JE, Wanger A. Mucormycosis of the gastrointestinal tract in
children: report of a case and review of the literature. Pediatr Infect
Dis J 1993;12:872–6.
44. Padhye AA, Koshi G, Anandi V, et al. First case of subcutaneous
zygomycosis caused by Saksenaea vasiformis in India. DiagnMicrobiol
Infect Dis 1988;9:69–77.
45. Parfrey NA. Improved diagnosis and prognosis of mucormycosis: a
clinicopathologic study of 33 cases. Medicine (Baltimore) 1986;65:
46. Zavasky DM, Samowitz W, Loftus T, Segal H, Carroll K. Gastroin-
testinal zygomycotic infection caused by Basidiobolus ranarum: case
report and review. Clin Infect Dis 1999;28:1244–8.
47. Korn EL, Graubard BL. Analysis of health surveys. New York, NY:
John Wiley and Sons, 1999.
48. Paultauf A. Mycosis mucorina. Arch Path Anat 1885;102:543.
49. Erdos MS, Butt K, Weinstein L. Mucormycotic endocarditis of the
pulmonary valve. JAMA 1972;222:951–3.
50. Kramer BS, Hernandez AD, Reddick RL, Levine AS. Cutaneous in-
farction: manifestation of disseminated mucormycosis. Arch Der-
51. Meyer RD, Kaplan MH, Ong M, Armstrong D. Cutaneous lesions in
disseminated mucormycosis. JAMA 1973;225:737–8.
52. Abedi E, Sismanis A, Choi K, Pastore P. Twenty-five years’ experience
treating cerebro-rhino-orbital mucormycosis. Laryngoscope1984;94:
53. Aboutanos MB, Joshi M, Scalea TM. Isolated pulmonary mucor-
mycosis in a patient with multiple injuries: a case presentation and
review of the literature. J Trauma 2003;54:1016–9.
54. Abramson E, Wilson D, Arky RA. Rhinocerebral phycomycosis in
association with diabetic ketoacidosis: report of twocasesandareview
of clinical and experimental experience with amphotericin B therapy.
Ann Intern Med 1967;66:735–42.
55. Abter EI, Lutwick SM, Chapnick EK, et al. Mucormycosis of amedian
sternotomy wound. Cardiovasc Surg 1994;2:474–7.
56. Adriaenssens K, Jorens PG, Meuleman L, Jeuris W, Lambert J. A black
necrotic skin lesion in an immunocompromised patient. Diagnosis:
cutaneous mucormycosis. Arch Dermatol 2000;136:1165–70.
57. Agger WA, Maki DG. Mucormycosis: a complication of critical care.
Arch Intern Med 1978;138:925–7.
58. Agh F, Spanik S, Gyarfas J, Horvath J, Krcmery V Jr. Three fatal cases
of disseminated mucormycosis associated with respiratory distress
syndrome and shock in patients with hematologic malignancies. In-
59. Akpunonu BE, Ansel G, Kaurich JD, Savolaine ER, Campbell EW Jr,
Myles JL. Zygomycosis mimicking paranasal malignancy. Am J Trop
Med Hyg 1991;45:390–8.
60. Al-Asiri RH, Van Dijken PJ, Mahmood MA, Al-Shahed MS, Rossi
ML, Osoba AO. Isolated hepatic mucormycosis in an immunocom-
petent child. Am J Gastroenterol 1996;91:606–7.
61. Al-Rikabi AC, Al-Dohayan AD, Al-Boukai AA. Invasive mucormy-
cosis in benign gastric ulcer. Saudi Med J 2000;21:287–90.
62. Altschuler G, Wadleigh J. Cephalic phycomycosis (Rhizipus species).
Ariz Med 1972;29:322–3.
63. Amin SB, Ryan RM, Metlay LA, Watson WJ. Absidia corymbifera
infections in neonates. Clin Infect Dis 1998;26:990–2.
64. Anaissie EJ, Shikhani AH. Rhinocerebral mucormycosis with internal
carotid occlusion: report of two cases and review of the literature.
Laryngoscope 1985;95(9 Pt 1):1107–13.
65. Anderson NE, Ali MR, Simpson IJ. Rhinocerebral mucormycosis
complicating poorly controlled diabetes mellitus: case report. N Z
Med J 1983;96:521–2.
66. Andrews EC, Rockwood CA, Cruz AB Jr. Unusual surgical infections:
gas gangrene necrotizing fasciitis phycomycosis synergistic bacterial
gangrene. Tex Med 1969;65:44–9.
67. Arisoy AE, Arisoy ES, Correa-Calderon A, Kaplan SL. Rhizopus nec-
rotizing cellulitis in a preterm infant: a case report and review of the
literature. Pediatr Infect Dis J 1993;12:1029–31.
68. Axelrod P, Kwon-Chung KJ, Frawley P, Rubin H. Chronic cystitis due
to Cokeromyces recurvatus: a case report. JInfectDis1987;155:1062–4.
Epidemiology of Zygomycosis • CID 2005:41 (1 September) • 645
69. Aydogdu I, Sari R, Mizrak B. Case report: rhinocerebralzygomycosis.
70. Bahna MS, Ward PH, Konrad HR. Nasopharyngeal mucormycotic
osteitis: a new syndrome characterized by initial presentation of mul-
tiple cranial nerve palsies. Otolaryngol Head Neck Surg 1980;88:
71. Balasubrahmanyan M, Chaudhuri S. A case of pulmonary mucor-
mycosis. Indian J Pathol Bacteriol 1963;6:60–2.
72. Balraj A, Anandi V, Raman R. Nasofacial conidiobolomycosis. Ear
Nose Throat J 1991;70:737–9.
73. Bank H, Shibolet S, Gilat T, Altmann G, Heller H. Mucormycosis of
head and neck structures: a case with survival. Br Med J 1962;5280:
74. Baraia J, Munoz P, Bernaldo de Quiros JC, Bouza E. Cutaneous mu-
cormycosis in a heart transplant patient associated with a peripheral
catheter. Eur J Clin Microbiol Infect Dis 1995;14:813–5.
75. Barnert J, Behr W, Reich H. An amphotericin B–resistant case of
rhinocerebral mucor mycosis. Infection 1985;13:134–6.
76. Bartrum RJ Jr, Watnick M, Herman PG. Roentgenographic findings
in pulmonary mucormycosis. Am J Roentgenol Radium Ther Nucl
77. Baum JL. Rhino-orbital mucormycosis occurring in an otherwise ap-
parently healthy individual. Am J Ophthalmol 1967;63:335–9.
78. Bearer EA, Nelson PR, Chowers MY, Davis CE. Cutaneous zygo-
mycosis caused by Saksenaea vasiformis in a diabetic patient. J Clin
79. Becker MH, Ngo N, BeranbaumSL. Mycoticinfectionoftheparanasal
sinuses: radiographic manifestations. Radiology 1968;90:49–51.
80. Bennett CL, Westbrook CA, Gruber B, Golomb HM. Hairy cell leu-
kemia and mucormycosis: treatment with alpha-2 interferon. Am J
81. Berenguer J, Munoz P, Parras F, Fernandez-Baca V, Hernandez-Sam-
pelayo T, Bouza E. Treatment of deep mycoses with liposomal am-
photericin B. Eur J Clin Microbiol Infect Dis 1994;13:504–7.
82. Berger CJ, Disque FC, Topazian RG. Rhinocerebral mucormycosis:
diagnosis and treatment. Report of two cases. Oral Surg Oral Med
Oral Pathol 1975;40:27–33.
83. Bergstrom L, Hemenway WG, Barnhart RA. Rhinocerebral and oto-
logic mucormycosis. Ann Otol Rhinol Laryngol 1970;79:70–81.
84. Berk M, Fink G, Ulyeda C. Rhinomucormycosis: report of a case
diagnosed by clinical signs. JAMA 1961;177:121–3.
85. Berns JS, Lederman MM, Greene BM. Nonsurgical cureofpulmonary
mucormycosis. Am J Med Sci 1984;287:42–4.
86. Bhaduri S, Kurrle E, Vanek E, Spanel R. Mucormycosis in the im-
munocompromised host. Infection 1983;11:170–2.
87. Bhattacharyya AK, Deshpande AR, Nayak SR, Kirtane MV, Ingle MV,
Vora IM. Rhinocerebral mucormycosis: an unusual case presentation.
J Laryngol Otol 1992;106:48–9.
88. Bittencourt AL, Ayala MA, Ramos EA. A new form of abdominal
zygomycosis different from mucormycosis: report of two cases and
review of the literature. Am J Trop Med Hyg 1979;28:564–9.
89. Bjorkholm M, Runarsson G, Celsing F, Kalin M, Petrini B, Engervall
P. Liposomal amphotericin B and surgery in the successful treatment
of invasive pulmonary mucormycosis in a patient with acute T-lym-
phoblastic leukemia. Scand J Infect Dis 2001;33:316–9.
90. Blatt SP, Lucey DR, DeHoff D, Zellmer RB. Rhinocerebral zygomy-
cosis in a patient with AIDS. J Infect Dis 1991;164:215–6.
91. Blodi FC, Hannah FT, Wadsworth JA. Lethal orbito-cerebral phy-
comycosis in otherwise healthy children. Am J Ophthalmol 1969;67:
92. Branton MH, Johnson SC, Brooke JD, Hasbargen JA. Peritonitis due
to Rhizopus in a patientundergoingcontinuousambulatoryperitoneal
dialysis. Rev Infect Dis 1991;13:19–21.
93. Bras G, Gordon CC, Emmons CW, Prendegast KM, Sugar M. A case
of phycomycosis observed in Jamaica: infection with Entomophthora
coronata. Am J Trop Med Hyg 1965;14:141–5.
94. Breiman A, Sadowsky D, Friedman J. Mucormycosis: discussion and
report of a case involving the maxillary sinus. Oral Surg Oral Med
Oral Pathol 1981;52:375–8.
95. Brown JF Jr, Gottlieb LS, McCormick RA. Pulmonary and rhinocer-
ebral mucormycosis: successful outcome with amphotericin B and
griseofulvin therapy. Arch Intern Med 1977;137:936–8.
96. Brown RB, Johnson JH, Kessinger JM, Sealy WC. Bronchovascular
mucormycosis in the diabetic: an urgent surgical problem. Ann
Thorac Surg 1992;53:854–5.
97. Bruun JN, Solberg CO, Hamre E, Janssen CJ Jr, Thunold S, Eide J.
Acute disseminated phycomycosis in a patient with impaired neu-
trophil granulocyte function. Acta Pathol Microbiol Scand [C].
98. Bryan GT, Read CH, Zimmerman GR. Disseminated mucormycosis
in a child with diabetes mellitus; a case report. J Iowa State Med Soc
99. Bullock JD, Jampol LM, Fezza AJ. Two cases of orbital phycomycosis
with recovery. Am J Ophthalmol 1974;78:811–5.
100. Burrow GN, Salmon RB, Nolan JP. Successful treatment of cerebral
mucormycosis with amphotericin B. JAMA 1963;183:370–2.
101. Butala A, Shah B, Cho YT, Schmidt MF. Isolated pulmonary mu-
cormycosis in an apparently normal host: a case report. J Natl Med
102. Caceres AM, Sardinas C, Marcano C, et al. Apophysomyces elegans
limb infection with a favorable outcome: case report and review. Clin
Infect Dis 1997;25:331–2.
103. Cagatay AA, Oncu SS, Calangu SS, Yildirmak TT, Ozsut HH, Eraksoy
HH. Rhinocerebral mucormycosis treated with 32 gram liposomal
amphotericin B and incomplete surgery: a case report. BMC Infect
104. Callard G, Wright C, Wray R, Minor G. False aneurysm due to mucor
following repair of a coarctation with a dacron prosthesis. J Thorac
Cardiovasc Surg 1971;61:181–5.
105. Calle S, Klatsky S. Intestinal phycomycosis (mucormycosis). Am J
Clin Pathol 1966;45:264–72.
106. Caraveo J, Trowbridge AA, Amaral BW, GreenJB 3rd,CainPT,Hurley
DL. Bone marrow necrosis associated with a Mucor infection. Am J
107. Carbone KM, Pennington LR, Gimenez LF, Burrow CR, Watson AJ.
Mucormycosis in renal transplant patients—a report of two cases and
review of the literature. Q J Med 1985;57:825–31.
108. Carpenter CF, Subramanian AK. Images in clinical medicine. Cuta-
neous zygomycosis (mucormycosis). N Engl J Med 1999;341:1891.
109. Carpenter DF, Brubaker LH, Powell RD Jr, Valsamis MP. Phycomy-
cotic thrombosis of the basilar artery. Neurology 1968;18:807–12.
110. Carr EJ, Scott P, Gradon JD. Fatal gastrointestinal mucormycosisthat
invaded the postoperative abdominal wall wound in an immuno-
competent host. Clin Infect Dis 1999;29:956–7.
111. Castelli JB, Pallin JL. Lethal rhinocerebral phycomycosis in a healthy
adult: a case report and review of the literature. Otolaryngology
112. Cefai C, Elliott TS, Nutton RW, Lockett AE, Pooley J. Zygomycetic
gangrenous cellulitis. Lancet 1987;2:1337–8.
113. Champion CK, Johnson TM. Rhino-orbital-cerebral phycomycosis.
Mich Med 1969;68:807–10.
114. Chandler FW, Watts JC, Kaplan W, Hendry AT, McGinnis MR, Ajello
L. Zygomycosis: report of four cases with formation of chlamydo-
conidia in tissue. Am J Clin Pathol 1985;84:99–103.
115. Chaudhry R, Venugopal P, Chopra P. Prosthetic mitral valve mucor-
mycosis caused by Mucor species. Int J Cardiol 1987;17:333–5.
116. Cherney CL, Chutuape A, Fikrig MK. Fatal invasive gastric mucor-
mycosis occurring with emphysematous gastritis: case report and lit-
erature review. Am J Gastroenterol 1999;94:252–6.
117. Chetchotisakd P, Boonma P, Sookpranee M, Pairojkul C. Rhinocer-
ebral mucormycosis: a report of eleven cases. Southeast Asian J Trop
Med Public Health 1991;22:268–73.
646 • CID 2005:41 (1 September) • Roden et al.
118. Chkhotua A, Yussim A, Tovar A, et al. Mucormycosis of the renal
allograft: case report and review of the literature. Transpl Int 2001;
119. Chugh KS, Sakhuja V, Gupta KL, et al. Renal mucormycosis: com-
puterized tomographic findings and their diagnostic significance. Am
J Kidney Dis 1993;22:393–7.
120. Clark RM.A case of mucormycosisoftheduodenum,liverandcecum.
121. Cloughley R, Kelehan J, Corbett-Feeney G, et al. Soft tissue infection
with Absidia corymbifera in a patient with idiopathic aplastic anemia.
J Clin Microbiol 2002;40:725–7.
122. Codish SD, Sheridan ID, Monaco AP. Mycotic wound infections: a
new challenge of the surgeon. Arch Surg 1979;114:831–5.
123. Coetzee AS, de Bruin GF. Mucormycosis: case report and review. S
Afr Med J 1974;48:2486–8.
124. Coffey MJ, Fantone J 3rd, Stirling MC, LynchJP3rd.Pseudoaneurysm
of pulmonary artery in mucormycosis: radiographic characteristics
and management. Am Rev Respir Dis 1992;145:1487–90.
125. Cohen MS, Brook CJ, Naylor B, Plouffe J, Silva J Jr, Weg JG. Pul-
monary phycomycetoma in a patient with diabetes mellitus. Am Rev
Respir Dis 1977;116:519–23.
126. Cohen-Abbo A, Bozeman PM, Patrick CC. Cunninghamella infec-
tions: review and report of two cases of Cunninghamella pneumonia
in immunocompromised children. Clin Infect Dis 1993;17:173–7.
127. Connor BA, Anderson RJ, Smith JW. Mucor mediastinitis. Chest
128. Couch L, Theilen F, Mader JT. Rhinocerebral mucormycosis with
cerebral extension successfully treated with adjunctive hyperbaric ox-
ygen therapy. Arch Otolaryngol Head Neck Surg 1988;114:791–4.
129. Craig NM, Lueder FL, Pensler JM, et al. Disseminated Rhizopus in-
fection in a premature infant. Pediatr Dermatol 1994;11:346–50.
130. Cuadrado LM, Guerrero A, Garcia Asenjo JA, Martin F, Palau E,
Garcia Urra D. Cerebral mucormycosis in two cases of acquired im-
munodeficiency syndrome. Arch Neurol 1988;45:109–11.
131. Cuadrado SP, Haberman S, Race GJ. Visceral mucormycosis (phy-
comycosis). Tex State J Med 1961;57:712–5.
132. Cussen LJ. Primary hypopituitary dwarfism with Fanconi’s hypo-
plastic anaemia syndrome, renal hypertension and phycomycosis: re-
port of a case. Med J Aust 1965;2:367–70.
133. Cuvelier I, Vogelaers D, Peleman R, et al. Two cases of disseminated
mucormycosis in patients with hematological malignancies and lit-
erature review. Eur J Clin Microbiol Infect Dis 1998;17:859–63.
134. Daly AL, Velazquez LA, Bradley SF, Kauffman CA. Mucormycosis:
association with deferoxamine therapy. Am J Med 1989;87:468–71.
135. Dansky AS, Lynne CM, Politano VA. Disseminated mucormycosis
with renal involvement. J Urol 1978;119:275–7.
136. Darja M, Davy MI. Pulmonary mucormycosis with cultural identi-
fication. Can Med Assoc J 1963;89:1235–8.
137. Darrisaw L, Hanson G, VesoleDH, KehlSC.Cunninghamellainfection
post bone marrow transplant: case report and review of the literature.
Bone Marrow Transplant 2000;25:1213–6.
138. Davila RM, Moser SA, Grosso LE. Renal mucormycosis: a case report
and review of the literature. J Urol 1991;145:1242–4.
139. de Biscop J, Mondie JM, Venries de la Guillaumie B, Peri G. Mu-
cormycosis in an apparently normal host: case study and literature
review. J Craniomaxillofac Surg 1991;19:275–8.
140. Deal WB, Johnson JE 3rd. Gastric phycomycosis: report of a case and
review of the literature. Gastroenterology 1969;57:579–86.
141. Dean DF, Ajello L, Irwin RS, Woelk WK, Skarulis GJ. Cranial zygo-
mycosis caused by Saksenaea vasiformis: case report. J Neurosurg
142. del Palacio Hernanz A, Fereres J, Larregla Garraus S, Rodriguez-
Noriega A, Sanz Sanz F. Nosocomial infection by Rhizomucor pusillus
in a clinical haematology unit. J Hosp Infect 1983;4:45–9.
143. Del Valle Zapico A, Rubio Suarez A, Mellado Encinas P, Morales
Angulo C, Cabrera Pozuelo E. Mucormycosis of the sphenoid sinus
in an otherwise healthy patient: case report and literature review. J
Laryngol Otol 1996;110:471–3.
144. Demirag A, Elkhammas EA, Henry ML, et al. Pulmonary Rhizopus
infection in a diabetic renal transplant recipient. Clin Transplant
145. Dennis JE, Rhodes KH, Cooney DR, Roberts GD. Nosocomical Rhi-
zopus infection (zygomycosis) in children. J Pediatr 1980;96:824–8.
146. DeSouza R, MacKinnon S, Spagnolo SV, Fossieck BE Jr. Treatment
of localized pulmonary phycomycosis. South Med J 1979;72:609–12.
147. DeWeese DD, Schleuning AJ 2nd, Robinson LB. Mucormycosis ofthe
nose and paranasal sinuses. Laryngoscope 1965;75:1398–407.
148. Dokmetas HS, Canbay E, Yilmaz S, et al. Diabetic ketoacidosis and
rhino-orbital mucormycosis. Diabetes ResClin Pract2002;57:139–42.
149. Dolman CL, Herd JA. Acute pancreatitis in pregnancy complicated
by renal cortical necrosis and cerebral mucormycosis. Can Med Assoc
150. Donohue JF, Scott RJ, Walker DH, Bromberg PA. Phycomycosis: a
cause of bronchial obstruction. South Med J 1980;73:734–6.
151. Dooley DP, Hollsten DA, Grimes SR, Moss J Jr. Indolent orbital apex
syndrome caused by occult mucormycosis. J Clin Neuroophthalmol
152. du Plessis PJ, Wentzel LF, Delport SD, van Damme E. Zygomycotic
necrotizing cellulitis in a premature infant. Dermatology 1997;195:
153. Dworzack DL, Pollock AS, Hodges GR, Barnes WG, Ajello L, Padhye
A. Zygomycosis of the maxillary sinus and palate caused by Basi-
diobolus haptosporus. Arch Intern Med 1978;138:1274–6.
154. Dwyer GK, Changus GW. Rhinomucormycosis resulting in fatal ce-
rebral mucormycosis. AMA Arch Otolaryngol 1958;67:619–23.
155. Dykhuizen RS, Kerr KN, Soutar RL. Air crescent sign and fatal hae-
moptysis in pulmonary mucormycosis. Scand J Infect Dis 1994;26:
156. Echols RM, Selinger DS, Hallowell C, Goodwin JS, Duncan MH,
Cushing AH. Rhizopus osteomyelitis: a case report and review. Am
J Med 1979;66:141–5.
157. Eckert HL, Khoury GH, Pore RS, Gilbert EF, Gaskell JR. Deep En-
tomophthora phycomycotic infection reported for the first time in the
United States. Chest 1972;61:392–4.
158. Eisenberg L, Wood T, Boles R. Mucormycosis. Laryngoscope 1977;
159. El-Ani AS, Dhar V. Disseminated mucormycosisinacaseofmetastatic
carcinoma. Am J Clin Pathol 1982;77:110–4.
160. Ericsson M, Anniko M, Gustafsson H, Hjalt CA, Stenling R, Tarnvik
A. A case of chronic progressive rhinocerebral mucormycosis treated
with liposomal amphotericin B and surgery. Clin Infect Dis 1993;16:
161. Espinoza CG, Halkias DG. Pulmonary mucormycosis as a compli-
cation of chronic salicylate poisoning. Am J Clin Pathol 1983;80:
162. Eucker J, Sezer O, Lehmann R, et al. Disseminated mucormycosis
caused by Absidia corymbifera leading to cerebral vasculitis. Infection
163. Everett ED, Pearson S, Rogers W. Rhizopus surgical wound infection
with elasticized adhesive tape dressings. Arch Surg 1979;114:738–9.
164. Faillo P, Sube H, Anderson N. Mucormycosis of the paranasalsinuses
and the maxilla. Oral Surg Oral Med Oral Pathol 1959;12:304–9.
165. Fergie JE, Fitzwater DS, Einstein P, Leggiadro RJ. Mucor peritonitis
associated with acute peritoneal dialysis. Pediatr Infect Dis J 1992;
166. Ferguson BJ, Mitchell TG, Moon R, Camporesi EM, Farmer J. Ad-
junctive hyperbaric oxygen for treatment of rhinocerebral mucor-
mycosis. Rev Infect Dis 1988;10:551–9.
167. Fermanis GG, Matar KS, Steele R. Endobronchial zygomycosis. Aust
N Z J Surg 1991;61:391–3.
168. Fernandez-Real JM, Lopez-Bermejo A, Ricart W. Cross-talk between
iron metabolism and diabetes. Diabetes 2002;51:2348–54.
169. Ferstenfeld JE, Cohen SH, Rose HD,RytelMW.Chronicrhinocerebral
Epidemiology of Zygomycosis • CID 2005:41 (1 September) • 647
phycomycosis in association with diabetes. Postgrad Med J 1977;53:
170. Fingerote RJ, Seigel S, Atkinson MH, Lewkonia RM. Disseminated
zygomycosis associated with systemic lupus erythematosus. J Rheu-
171. Fingeroth JD, Roth RS, Talcott JA, Rinaldi MG. Zygomycosis due to
Mucor circinelloides in a neutropenic patient receiving chemotherapy
for acute myelogenous leukemia. Clin Infect Dis 1994;19:135–7.
172. Fisher EW, Toma A, Fisher PH, Cheesman AD. Rhinocerebral mu-
cormycosis: use of liposomal amphotericin B. J Laryngol Otol
173. Foley FD, Shuck JM. Burn-wound infection with phycomycetes re-
quiring amputation of hand. JAMA 1968;203:596.
174. Fong KM, Seneviratne EM, McCormack JG. Mucor cerebral abscess
associated with intravenous drug abuse. Aust N Z J Med 1990;20:
175. Forteza G, Burgeno M, Martorell V, Sierra I. Rhinocerebral mucor-
mycosis: presentation of two cases and review of the literature. J
Craniomaxillofac Surg 1988;16:80–4.
176. Fortun J, Cobo J, Canal J, Martinez-San Millan J. Post-traumatic
cranial mucormycosis in an immunocompetent patient. J Oral Max-
illofac Surg 1995;53:1099–102.
177. Foss NT, Rocha MR, Lima VT, Velludo MA, Roselino AM. Ento-
mophthoramycosis: therapeutic success by using amphotericin B and
terbinafine. Dermatology 1996;193:258–60.
178. Foushee S, Beck WC. Mucormycosis of the central nervous system;
a case report. N C Med J 1956;17:26–31.
179. Fukushima T, Sumazaki R, Shibasaki M, et al. Successful treatment
of invasive thoracopulmonary mucormycosis in a patient with acute
lymphoblastic leukemia. Cancer 1995;76:895–9.
180. Funada H, Miyake Y, Kanamori K, Okafuji K, Machi T, Matsuda T.
Fluconazole therapy for pulmonary mucormycosiscomplicatingacute
leukemia. Jpn J Med 1989;28:228–31.
181. Gaing AA, Corbalan F, Weinberger J. Phycomycosis (mucormycosis)
in differential diagnosis of cerebral mass lesions in intravenous drug
users. Mt Sinai J Med 1992;59:69–71.
182. Gale AM, Kleitsch WP. Solitary pulmonary nodule due to phyco-
mycosis (mucormycosis). Chest 1972;62:752–5.
183. Galetta SL, Wulc AE, Goldberg HI, Nichols CW, Glaser JS. Rhino-
cerebral mucormycosis: management and survival after carotid oc-
clusion. Ann Neurol 1990;28:103–7.
184. Gans RO, Strack van Schijndel RJ, Laarman DA, Stilma JS, Thijs LG.
Fatal rhinocerebral mucormycosis and diabetic ketoacidosis. Neth J
185. Garcia-CovarrubiasL, BartlettR,BarrattDM,WassermannRJ.Rhino-
orbitocerebral mucormycosis attributable to Apophysomyces elegans
in an immunocompetent individual: case report and review of the
literature. J Trauma 2001;50:353–7.
186. Garey KW, Pendland SL, Huynh VT, Bunch TH, Jensen GM, Pursell
KJ. Cunninghamella bertholletiae infection in a bone marrow trans-
plant patient: amphotericin lung penetration, MIC determinations,
and review of the literature. Pharmacotherapy 2001;21:855–60.
187. Gartenberg G, Bottone EJ, Keusch GT, Weitzman I. Hospital-acquired
mucormycosis (Rhizopus rhizopodiformis) of skin and subcutaneous
tissue: epidemiology, mycology and treatment. N Engl J Med 1978;
188. Gass JD. Acute orbital mucormycosis: report of two cases. Arch
189. Gaviria JM, Grohskopf LA, Barnes R, Root RK. Successful treatment
of rhinocerebral zygomycosis: a combined-strategy approach. Clin
Infect Dis 1999;28:160–1.
190. Gaziev D, Baronciani D, Galimberti M, et al. Mucormycosis after
bone marrow transplantation: report of four cases in thalassemia and
review of the literature. Bone Marrow Transplant 1996;17:409–14.
191. Geller JD, Peters MS, Su WP. Cutaneous mucormycosis resembling
superficial granulomatous pyoderma in an immunocompetent host.
J Am Acad Dermatol 1993;29:462–5.
192. Ginsberg J, Spaulding AG, Laing VO. Cerebral phycomycosis (mu-
cormycosis) with ocular involvement. Am J Ophthalmol 1966;62:
193. Gokcil Z, Odabasi Z, Kutukcu Y, Umudum H, Vural O, Yardim M.
Rhino-orbito-cerebral mucormycosis. J Neurol 1998;245:689–90.
194. Goldstein MF, Dvorin DJ, Dunsky EH, Lesser RW, Heuman PJ, Loose
JH. Allergic Rhizomucor sinusitis. J Allergy Clin Immunol 1992;90(3
195. Gollard R, Rabb C, Larsen R, Chandrasoma P. Isolated cerebral mu-
cormycosis: case report and therapeutic considerations.Neurosurgery
196. Gonis G, Starr M. Fatal rhinoorbital mucormycosis caused by Sak-
senaea vasiformis in an immunocompromised child. PediatrInfectDis
197. Gonzalez CE, Couriel DR, Walsh TJ. Disseminated zygomycosis in a
neutropenic patient: successful treatment with amphotericin B lipid
complex and granulocyte colony-stimulating factor. Clin Infect Dis
198. Goodnight J, Dulguerov P, Abemayor E. Calcified Mucor fungus ball
of the maxillary sinus. Am J Otolaryngol 1993;14:209–10.
199. Gordon G, Indeck M, Bross J, Kapoor DA, Brotman S. Injury from
silage wagon accident complicated by mucormycosis. J Trauma
200. Grauer ME, Bokemeyer C, Welte T, Freund M, Link H. Successful
treatment of Mucor pneumonia in a patient with relapsed lympho-
blastic leukemia after bone marrow transplantation. Bone Marrow
201. Gribetz AR, Chuang MT, Burrows L, Teirstein AS. Rhizopus lung
abscess in renal transplant patient successfully treated by lobectomy.
202. Griffin GK, Ellis AR, Kim TC. Cure of isolated pulmonary mucor-
mycosis: case report. Va Med 1983;110:550–2.
203. Grim PF, 3rd, Demello D, Keenan WJ. Disseminated zygomycosis in
a newborn. Pediatr Infect Dis 1984;3:61–3.
204. Gunson HH, Bowden DH. Cerebral mucormycosis; report of a case.
AMA Arch Pathol 1955;60:440–3.
205. Gupta KL, Joshi K, Pereira BJ, Singh K. Disseminated mucormycosis
presenting with acute renal failure. Postgrad Med J 1987;63:297–9.
206. Gussen R, Canalis RF. Mucormycosis of the temporal bone. Ann Otol
Rhinol Laryngol 1982;91(1 Pt 1):27–32.
207. Hadley GP. Neonatal mucormycosis. P N G Med J 1981;24:54–6.
208. Haim S, Better OS, Lichtig C, Erlik D, Barzilai A. Rhinocerebral
mucormycosis following kidney transplantation. Isr J Med Sci 1970;6:
209. Hall JC, Brewer JH, Reed WA, Steinhaus DM, Watson KR. Cutaneous
mucormycosis in a heart transplant patient. Cutis 1988;42:183–6.
210. Hamill R, Oney LA, Crane LR. Successful therapy for rhinocerebral
mucormycosis with associated bilateral brain abscesses. Arch Intern
211. Hamilton JF, Bartkowski HB, Rock JP. Management of CNS mucor-
mycosis in the pediatric patient. Pediatr Neurosurg 2003;38:212–5.
212. Hammer GS, Bottone EJ, Hirschman SZ. Mucormycosis in a trans-
plant recipient. Am J Clin Pathol 1975;64:389–98.
213. Hammond DE, Winkelmann RK. Cutaneous phycomycosis: report
of three cases with identification of Rhizopus. Arch Dermatol 1979;
214. Handzel O, Landau Z, Halperin D. Liposomal amphotericin B treat-
ment for rhinocerebral mucormycosis: how much is enough? Rhi-
215. Hanse MC, Nijssen PC. Unilateral palsy of all cranial nerves (Garcin
syndrome) in a patient with rhinocerebral mucormycosis. J Neurol
216. Harada M, Manabe T, Yamashita K, Okamoto N. Pulmonary mu-
cormycosis with fatal massive hemoptysis. Acta Pathol Jpn 1992;42:
217. Harris JS. Mucormycosis; report of a case. Pediatrics1955;16:857–67.
648 • CID 2005:41 (1 September) • Roden et al. Download full-text
218. Hauch TW. Pulmonary mucormycosis: another cure. Chest 1977;72:
219. Hay RJ, Campbell CK, Marshall WM, Rees BI, PincottJ.Disseminated
zygomycosis (mucormycosis) caused by Saksenaea vasiformis. J Infect
220. Heinemann S. Phycomycosis as postoperative complication of urol-
ogic surgery. Urology 1981;17:65–7.
221. Hennessy MJ, Mosher TF. Mucormycosis infection of an upper ex-
tremity. J Hand Surg [Am] 1981;6:249–52.
222. Henriquez M, Levy R, Raja RM, Kramer MS, Rosenbaum JL. Mu-
cormycosis in a renal transplant recipient with successful outcome.
223. Herbrecht R, Letscher-Bru V, Bowden RA, et al. Treatment of 21 cases
of invasive mucormycosis with amphotericin B colloidal dispersion.
Eur J Clin Microbiol Infect Dis 2001;20:460–6.
224. Herman VS, Hurwitz S, Segal F. Multiple pulmonary abscesses re-
sulting from pulmonary mucormycosis. Heart Lung 1980;9:514–7.
225. Hoffman RM. Chronic endobronchial mucormycosis. Chest1987;91:
226. Holtom PD, Obuch AB, Ahlmann ER, Shepherd LE, Patzakis MJ.
Mucormycosis of the tibia: a case report and review of the literature.
Clin Orthop Relat Res 2000;381:222–8.
227. Horowitz A, Dinbar A, Tulcinsky DB. Isolated primary intestinalmu-
cormycosis: a case report. Isr J Med Sci 1974;10:1143–7.
228. HosseiniM, LeeJ.Gastrointestinalmucormycosismimickingischemic
colitis in a patient with systemic lupus erythematosus. Am J Gas-
229. Hsu J, Clayman JA, Geha AS. Survival of a recipient of renal trans-
plantation after pulmonary phycomycosis. Ann Thorac Surg 1989;
230. Hughes C, Driver SJ, Alexander KA. Successful treatment of abdom-
inal wall Rhizopus necrotizing cellulitis in a preterm infant. Pediatr
Infect Dis J 1995;14:336.
231. Humphry RC, Wright G, Rich WJ, Simpson R. Acute proptosis and
blindness in a patient with orbital phycomycosis.JRSocMed1989;82:
232. Hunter AJ, Bryant RE. Abdominal wall mucormycosis successfully
treated with amphotericin and itraconazole. J Infect 2002;44:203–4.
233. Husari AW, Jensen WA, Kirsch CM, et al. Pulmonary mucormycosis
presenting as an endobronchial lesion. Chest 1994;106:1889–91.
234. Hutter RV. Phycomycetous infection (mucormycosis) in cancer pa-
tients: a complication of therapy. Cancer 1959;12:330–50.
235. Hyatt DS, Young YM, Haynes KA, Taylor JM, McCarthy DM, Rogers
TR. Rhinocerebral mucormycosis following bone marrow transplan-
tation. J Infect 1992;24:67–71.
236. Ignelzi RJ, VanderArk GD. Cerebral mucormycosis following open
head trauma: case report. J Neurosurg 1975;42:593–6.
237. Ingram CW, Sennesh J, Cooper JN, Perfect JR. Disseminated zygo-
mycosis: report of four cases and review. Rev Infect Dis 1989;11:
238. Iqbal SM, Scheer RL. Myocardial mucormycosis with emboli in a
hemodialysis patient. Am J Kidney Dis 1986;8:455–8.
239. Isaacson C, Levin SE. Gastro-intestinal mucormycosis in infancy. S
Afr Med J 1961;35:581–4.
240. Jain JK, Markowitz A, Khilanani PV, Lauter CB. Localized mucor-
mycosis following intramuscular corticosteroid: case report and re-
view of the literature. Am J Med Sci 1978;275:209–16.
241. Jantunen E, Kolho E, Ruutu P, et al. Invasivecutaneousmucormycosis
caused by Absidia corymbifera after allogeneic bone marrow trans-
plantation. Bone Marrow Transplant 1996;18:229–30.
242. Jimenez C, Lumbreras C, Aguado JM, et al. Successful treatment of
mucor infection after liver or pancreas-kidney transplantation.Trans-
243. Johnson AS, Ranson M, Scarffe JH, Morgenstern GR, Shaw AJ, Op-
penheim BA. Cutaneous infection with Rhizopus oryzae and Asper-
gillus niger following bone marrow transplantation. J Hosp Infect
244. Johnson GM, Baldwin JJ. Pulmonary mucormycosis and juvenile di-
abetes. Am J Dis Child 1981;135:567–8.
245. Johnson PC, Satterwhite TK, Monheit JE, ParksD. Primarycutaneous
mucormycosis in trauma patients. J Trauma 1987;27:437–41.
246. Kamalam A, Thambiah AS. Cutaneous infection by Syncephalastrum.
247. Kamalam A, Thambiah AS. Muscle invasion by Basidiobolus hapto-
sporus. Sabouraudia 1984;22:273–7.
248. Kaplan AH, Poza-Juncal E, Shapiro R, Stapleton JT. Cure of mucor-
mycosis in a renal transplant patient receiving ciclosporin with main-
tenance of immunosuppression. Am J Nephrol 1988;8:139–42.
249. Kemna ME, Neri RC, Ali R, Salkin IF. Cokeromyces recurvatus, a
mucoraceous zygomycete rarely isolated in clinical laboratories.JClin
250. Khardori N, Hayat S, Rolston K, Bodey GP. Cutaneous Rhizopus and
Aspergillus infections in five patients with cancer. Arch Dermatol
251. Kimura M, Smith MB, McGinnis MR. Zygomycosis due to Apophy-
somyces elegans: report of 2 cases and review of the literature. Arch
Pathol Lab Med 1999;123:386–90.
252. King JCJr, Dunphy D.Fatalphycomycosiswithoutunderlyingdisease.
J Iowa Med Soc 1972;62:485–8.
253. Kitabayashi A, Hirokawa M, Yamaguchi A, Takatsu H, Miura AB.
Invasive pulmonary mucormycosis with rupture of the thoracicaorta.
Am J Hematol 1998;58:326–9.
254. Kocak R, Tetiker T, Kocak M, Baslamisli F, Zorludemir S, Gonlusen
G. Fluconazole in the treatment of three cases of mucormycosis. Eur
J Clin Microbiol Infect Dis 1995;14:559–61.
255. Kofteridis DP, Karabekios S, Panagiotides JG, et al. Successful treat-
ment of rhinocerebral mucormycosis with liposomal amphotericin B
and surgery in two diabetic patients with renal dysfunction. J Che-
256. Kohn R, Hepler R. Management of limited rhino-orbital mucor-
mycosis without exenteration. Ophthalmology 1985;92:1440–4.
257. Kontoyianis DP, Vartivarian S, Anaissie EJ, Samonis G, Bodey GP,
Rinaldi M. Infections due to Cunninghamella bertholletiae in patients
with cancer: report of three cases and review. Clin Infect Dis 1994;
258. Kumar S, Trivedi HL, Smith EK. Letter: rhinocerebral mucormycosis
in a renal transplant patient. J Oral Surg 1976;34:583.
259. Kyrmizakis DE, Doxas PG, Hajiioannou JK, Papadakis CE. Palate
ulcer due to mucormycosis. J Laryngol Otol 2002;116:146–7.
260. Lake FR, McAleer R, Tribe AE. Pulmonary mucormycosis without
underlying systemic disease. Med J Aust 1988;149:323–6.
261. Lakshmi V, Rani TS, Sharma S, et al. Zygomycotic necrotizingfasciitis
caused by Apophysomyces elegans. J Clin Microbiol 1993;31:1368–9.
262. Landau JW, Newcomer VD. Acute cerebral phycomycosis (mucor-
mycosis): report of a pediatric patient successfully treated with am-
photericin B and cycloheximide and review of the pertinentliterature.
J Pediatr 1962;61:363–85.
263. Latif S, Saffarian N, Bellovich K, Provenzano R. Pulmonary mucor-
mycosis in diabeticrenalallograftrecipients.AmJKidneyDis1997;29:
264. LaVange LM, Koch GG, Schwartz TA. Applying sample survey meth-
ods to clinical trials data. Stat Med 2001;20:2609–23.
265. Lawrence RM, Snodgrass WT, Reichel GW, Padhye AA, Ajello L,
Chandler FW. Systemic zygomycosiscausedbyApophysomyceselegans.
J Med Vet Mycol 1986;24:57–65.
266. LeCompte P, Meissner W. Mucormycosis of the central nervous sys-
tem associated with hemochromatosis: report of a case. Am J Pathol
267. Lee CH, Lee CJ, Hsueh C, Lee MC. Pulmonary mucormycosis: the
first case with preoperative diagnosis and successfulsurgicaltreatment
in Taiwan. J Formos Med Assoc 1990;89:1096–8.
268. Lee FY, Mossad SB, Adal KA. Pulmonary mucormycosis: the last 30
years. Arch Intern Med 1999;159:1301–9.
269. Leleu X, Sendid B, Fruit J, et al. Combined anti-fungal therapy and